Moderna Launches $2B Convertible Notes Offering to Fund Oncology Push
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna is selling $2 billion of convertible senior notes due 2032 in a private placement. Proceeds are earmarked for general corporate purposes, including investing in its oncology business and repaying debt. The offering follows last week's positive Phase 3 data for its personalized cancer vaccine with Merck, which sent shares up 177% before a pullback. The convertible structure limits immediate dilution but adds potential future share overhang. The company reported a Q2 net loss of $782 million, so the capital raise strengthens its balance sheet as it advances its oncology pipeline.
At the time of this announcement, MRNA was trading at $142.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.7B. The 52-week trading range was $22.28 to $176.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.